Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- CALM -6.9%
Select financial related names showing weakness:
- BAC -2.5%, MS -2.3%, C -2.2%, GS -1.9%, JPM -1.8%, WFC-1.8%, DB -1.1%
Select metal producers trading lower:
- CLF -5%, AKS -5%, X -4.2%, AA -3.9%, FCX -3.8%, BHP -2.7%,BBL -1.5%, RIO -1.5%
Select oil/gas related names showing early weakness:
- KEY -1.9%, WLL -1.8%, PBR -1.7%, CHK -1.1%
Other news:
- FOMX -44.6% (announces topline results of its two Phase 3 clinical trials investigating FMX101; did not demonstrate statistical significance on one of the two co-primary endpoints in Trial 04)
- ARQL -14.9% (reports that its partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan, and that the trial did not meet its primary endpoint)
- IPI -4.3% (announced that Brian Frantz, Senior Vice President and Chief Accounting Officer of Intrepid, will resign)
- VALE -3.2% (confirms Court issued ruling dismissing most of the claims against Vale and the individual defendants in securities class action suit)
Analyst comments:
- SAP -0.8% (downgraded to Neutal from Buy at UBS